Other CDK6 PROTACs designed for selective degradation of CDK6 over CDK4 using CDK inhibitors and CRBN ligands include BSJ-03-123 (Supplementary Table S1) (against AML) (Brand et al., 2019) and CP-10 (Supplementary Table S1) (most potent degrader from a CDK6 degrader library) which not only degraded mutated CDK6 that underwent overexpression, but also inhibited hematopoietic malignant cell proliferation (Su et al., 2019). Here, CDK6 is linked to acute myeloid leukemia.